{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T01:59:32Z","timestamp":1792202372248,"version":"4.4.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T00:00:00Z","timestamp":1661212800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100022113","name":"University of Health and Allied Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022113","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009914","name":"Makerere University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009914","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019273","name":"National Institute for Medical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019273","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.ijid.2022.08.020","type":"journal-article","created":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T14:05:59Z","timestamp":1662386759000},"page":"192-199","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Lumefantrine plasma concentrations in uncontrolled conditions among patients treated with artemether-lumefantrine for uncomplicated plasmodium falciparum malaria in Mwanza, Tanzania"],"prefix":"10.1016","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5237-2904","authenticated-orcid":false,"given":"Karol J","family":"Marwa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6541-9791","authenticated-orcid":false,"given":"Anthony C","family":"Liwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eveline T","family":"Konje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley","family":"Mwita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erasmus","family":"Kamugisha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4567-2957","authenticated-orcid":false,"given":"G\u00f6te","family":"Swedberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2022.08.020_bib0001","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3109\/03602532.2013.783062","article-title":"Cytochrome P450 pharmacogenetics in African populations","volume":"45","author":"Alessandrini","year":"2013","journal-title":"Drug metabolism reviews"},{"key":"10.1016\/j.ijid.2022.08.020_bib0002","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1365-3156.2006.01784.x","article-title":"How much fat is necessary to optimize lumefantrine oral bioavailability?","volume":"12","author":"Ashley","year":"2007","journal-title":"Tropical Medicine & International Health"},{"key":"10.1016\/j.ijid.2022.08.020_bib0003","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1365-3156.2006.01785.x","article-title":"Pharmacokinetic study of artemether\u2013lumefantrine given once daily for the treatment of uncomplicated multidrug-resistant falciparum malaria","volume":"12","author":"Ashley","year":"2007","journal-title":"Tropical Medicine & International Health"},{"key":"10.1016\/j.ijid.2022.08.020_bib0004","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.pt.2007.11.008","article-title":"Antimalarial dosing regimens and drug resistance","volume":"24","author":"Barnes","year":"2008","journal-title":"Trends in parasitology"},{"key":"10.1016\/j.ijid.2022.08.020_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1475-2875-8-204","article-title":"Measurement of adherence, drug concentrations and the effectiveness of artemether-lumefantrine, chlorproguanil-dapsone or sulphadoxine-pyrimethamine in the treatment of uncomplicated malaria in Malawi","volume":"8","author":"Bell","year":"2009","journal-title":"Malaria journal"},{"key":"10.1016\/j.ijid.2022.08.020_bib0006","doi-asserted-by":"crossref","first-page":"915","DOI":"10.2217\/pgs-2019-0046","article-title":"Pharmacogenomics in the Nigerian population: the past, the present and the future","volume":"20","author":"Bolaji","year":"2019","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.ijid.2022.08.020_bib0007","first-page":"434","article-title":"The effect of food consumption on lumefantrine bioavailability in African children receiving artemether\u2013lumefantrine crushed or dispersible tablets (Coartem\u00ae) for acute uncomplicated Plasmodium falciparum malaria","volume":"15","author":"Borrmann","year":"2010","journal-title":"Tropical Medicine & International Health"},{"key":"10.1016\/j.ijid.2022.08.020_bib0008","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1146\/annurev.genom.9.081307.164258","article-title":"African genetic diversity: implications for human demographic history, modern human origins, and complex disease mapping","volume":"9","author":"Campbell","year":"2008","journal-title":"Annu. Rev. Genomics Hum. Genet."},{"key":"10.1016\/j.ijid.2022.08.020_bib0009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1475-2875-5-59","article-title":"Supervised versus unsupervised antimalarial treatment with six-dose artemether-lumefantrine: pharmacokinetic and dosage-related findings from a clinical trial in Uganda","volume":"5","author":"Checchi","year":"2006","journal-title":"Malaria journal"},{"key":"10.1016\/j.ijid.2022.08.020_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1475-2875-11-177","article-title":"The effects of serum lipids on the in vitro activity of lumefantrine and atovaquone against Plasmodium falciparum","volume":"11","author":"Chotivanich","year":"2012","journal-title":"Malaria journal"},{"key":"10.1016\/j.ijid.2022.08.020_bib0011","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1517\/17425255.2014.894020","article-title":"Cytochrome P450 pharmacogenetics in African populations: implications for public health","volume":"10","author":"Dandara","year":"2014","journal-title":"Expert opinion on drug metabolism & toxicology"},{"key":"10.1016\/j.ijid.2022.08.020_bib0012","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1475-2875-8-S1-S4","article-title":"Understanding the pharmacokinetics of Coartem\u00ae","volume":"8","author":"Djimd\u00e9","year":"2009","journal-title":"Malaria journal"},{"key":"10.1016\/j.ijid.2022.08.020_bib0013","doi-asserted-by":"crossref","first-page":"682","DOI":"10.2174\/1389200220666190806141825","article-title":"Association Between CYP3A4 and CYP3A5 Genotypes and Cyclosporine's Blood Levels and Doses among Jordanian Kidney Transplanted Patients","volume":"20","author":"El-Shair","year":"2019","journal-title":"Current Drug Metabolism"},{"key":"10.1016\/j.ijid.2022.08.020_bib0014","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1038\/sj.ki.5000325","article-title":"The influence of CYP3A gene polymorphisms on cyclosporine dose requirement in renal allograft recipients","volume":"69","author":"Eng","year":"2006","journal-title":"Kidney international"},{"key":"10.1016\/j.ijid.2022.08.020_bib0015","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1046\/j.1365-2125.1998.00830.x","article-title":"Population pharmacokinetics and therapeutic response of CGP 56697 (artemether+ benflumetol) in malaria patients","volume":"46","author":"Ezzet","year":"1998","journal-title":"British journal of clinical pharmacology"},{"key":"10.1016\/j.ijid.2022.08.020_bib0016","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1128\/AAC.44.3.697-704.2000","article-title":"Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria","volume":"44","author":"Ezzet","year":"2000","journal-title":"Antimicrobial agents and chemotherapy"},{"key":"10.1016\/j.ijid.2022.08.020_bib0017","doi-asserted-by":"crossref","first-page":"525","DOI":"10.4269\/ajtmh.2004.71.525","article-title":"Adherence to a six-dose regimen of artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Uganda","volume":"71","author":"Fogg","year":"2004","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.ijid.2022.08.020_bib0018","doi-asserted-by":"crossref","first-page":"e8184","DOI":"10.1371\/journal.pone.0008184","article-title":"Residual antimalarials in malaria patients from Tanzania\u2013implications on drug efficacy assessment and spread of parasite resistance","volume":"4","author":"Hodel","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.ijid.2022.08.020_bib0019","first-page":"1","article-title":"Population pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients","volume":"12","author":"Hodel","year":"2013","journal-title":"Malaria journal"},{"key":"10.1016\/j.ijid.2022.08.020_bib0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1475-2875-9-48","article-title":"Adherence to and acceptability of artemether-lumefantrine as first-line anti-malarial treatment: evidence from a rural community in Tanzania","volume":"9","author":"Kabanywanyi","year":"2010","journal-title":"Malaria journal"},{"key":"10.1016\/j.ijid.2022.08.020_bib0021","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2174\/1875692111201010087","article-title":"Pharmacogenetics research developments in Africa: a focus on Malawi","volume":"10","author":"Kampira","year":"2012","journal-title":"Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics)"},{"key":"10.1016\/j.ijid.2022.08.020_bib0022","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1093\/aje\/kwh294","article-title":"CYP3A4 polymorphisms\u2014potential risk factors for breast and prostate cancer: a HuGE review","volume":"160","author":"Keshava","year":"2004","journal-title":"American journal of epidemiology"},{"key":"10.1016\/j.ijid.2022.08.020_bib0023","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jchromb.2013.10.037","article-title":"Method development and validation for simultaneous determination of lumefantrine and its major metabolite, desbutyl lumefantrine in human plasma using RP-HPLC\/UV detection","volume":"944","author":"Khuda","year":"2014","journal-title":"Journal of chromatography B"},{"key":"10.1016\/j.ijid.2022.08.020_bib0024","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12936-020-3150-y","article-title":"Usefulness of day 7 lumefantrine plasma concentration as a predictor of malaria treatment outcome in under-fives children treated with artemether-lumefantrine in Tanzania","volume":"19","author":"Kilonzi","year":"2020","journal-title":"Malaria journal"},{"key":"10.1016\/j.ijid.2022.08.020_bib0025","doi-asserted-by":"crossref","first-page":"6375","DOI":"10.1128\/AAC.00267-15","article-title":"Lumefantrine and desbutyl-lumefantrine population pharmacokinetic-pharmacodynamic relationships in pregnant women with uncomplicated Plasmodium falciparum malaria on the Thailand-Myanmar border","volume":"59","author":"Kloprogge","year":"2015","journal-title":"Antimicrobial agents and chemotherapy"},{"key":"10.1016\/j.ijid.2022.08.020_bib0026","first-page":"1","article-title":"Population pharmacokinetics of lumefantrine in pregnant and nonpregnant women with uncomplicated Plasmodium falciparum malaria in Uganda","volume":"2","author":"Kloprogge","year":"2013","journal-title":"CPT: pharmacometrics & systems pharmacology"},{"key":"10.1016\/j.ijid.2022.08.020_bib0027","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002579","article-title":"Artemether-lumefantrine dosing for malaria treatment in young children and pregnant women: a pharmacokinetic-pharmacodynamic meta-analysis","volume":"15","author":"Kloprogge","year":"2018","journal-title":"PLoS medicine"},{"key":"10.1016\/j.ijid.2022.08.020_bib0028","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/j.1365-2125.2007.03050.x","article-title":"Population pharmacokinetics of chloroquine and sulfadoxine and treatment response in children with malaria: suggestions for an improved dose regimen","volume":"65","author":"Obua","year":"2008","journal-title":"British journal of clinical pharmacology"},{"key":"10.1016\/j.ijid.2022.08.020_bib0029","first-page":"1","article-title":"Artemether-lumefantrine treatment of uncomplicated Plasmodium falciparum malaria: a systematic review and meta-analysis of day 7 lumefantrine concentrations and therapeutic response using individual patient data","volume":"13","year":"2015","journal-title":"BMC medicine"},{"key":"10.1016\/j.ijid.2022.08.020_bib0030","series-title":"Methods and techniques for clinical trials on antimalarial drug efficacy: genotyping to identify parasite populations: informal consultation organized by the Medicines for Malaria Venture and cosponsored by the World Health Organization","author":"Organization","year":"2008"},{"key":"10.1016\/j.ijid.2022.08.020_bib0032","series-title":"Basic malaria microscopy: Part I. Learner's guide","author":"Organization","year":"2010"},{"key":"10.1016\/j.ijid.2022.08.020_bib0033","series-title":"Guidelines for the treatment of malaria","author":"Organization","year":"2015"},{"key":"10.1016\/j.ijid.2022.08.020_bib0034","unstructured":"Organization, W.H., 2015b. Methods for surveillance of antimalarial drug efficacy. 2009."},{"key":"10.1016\/j.ijid.2022.08.020_bib0035","series-title":"World malaria report 2015","author":"Organization","year":"2016"},{"key":"10.1016\/j.ijid.2022.08.020_bib0036","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1124\/dmd.31.12.1507","article-title":"Modeling of intestinal drug absorption: roles of transporters and metabolic enzymes (for the Gillette Review Series)","volume":"31","author":"Pang","year":"2003","journal-title":"Drug metabolism and disposition"},{"key":"10.1016\/j.ijid.2022.08.020_bib0037","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1093\/cid\/ciw291","article-title":"Antiretroviral choice for HIV impacts antimalarial exposure and treatment outcomes in Ugandan children","volume":"63","author":"Parikh","year":"2016","journal-title":"Reviews of Infectious Diseases"},{"key":"10.1016\/j.ijid.2022.08.020_bib0038","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1517\/17425255.2011.608660","article-title":"The pharmacogenetics of antimalaria artemisinin combination therapy","volume":"7","author":"Piedade","year":"2011","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.ijid.2022.08.020_bib0039","first-page":"1","article-title":"Pharmacometrics: opportunity for reducing disease burden in the developing world: the case of Africa","volume":"2","author":"Pillai","year":"2013","journal-title":"CPT: Pharmacometrics & Systems Pharmacology"},{"key":"10.1016\/j.ijid.2022.08.020_bib0040","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1086\/503423","article-title":"Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant Plasmodium falciparum malaria","volume":"42","author":"Price","year":"2006","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.ijid.2022.08.020_bib0041","article-title":"Sex differences in drug disposition","author":"Soldin","year":"2011","journal-title":"Journal of Biomedicine and Biotechnology 2011"},{"key":"10.1016\/j.ijid.2022.08.020_bib0042","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13071-018-2895-4","article-title":"Plasmodium falciparum msp 1 and msp 2 genetic diversity and allele frequencies in parasites isolated from symptomatic malaria patients in Bobo-Dioulasso","volume":"11","author":"Som\u00e9","year":"2018","journal-title":"Parasites & vectors"},{"key":"10.1016\/j.ijid.2022.08.020_bib0043","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1128\/AAC.01700-12","article-title":"Effect of single nucleotide polymorphisms in cytochrome P450 isoenzyme and N-acetyltransferase 2 genes on the metabolism of artemisinin-based combination therapies in malaria patients from Cambodia and Tanzania","volume":"57","author":"Staehli Hodel","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2022.08.020_bib0044","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/FPC.0b013e32833ccd56","article-title":"Effects of the CYP3A5* 3 variant on cyclosporine exposure and acute rejection rate in renal transplant patients: a meta-analysis","volume":"20","author":"Tang","year":"2010","journal-title":"Pharmacogenetics and genomics"},{"key":"10.1016\/j.ijid.2022.08.020_bib0045","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1093\/infdis\/jiw338","article-title":"Population pharmacokinetics and pharmacodynamics of lumefantrine in young Ugandan children treated with artemether-lumefantrine for uncomplicated malaria","volume":"214","author":"Tchaparian","year":"2016","journal-title":"The Journal of infectious diseases"},{"key":"10.1016\/j.ijid.2022.08.020_bib0046","unstructured":"TEKETE, M.M., 2020. Day 7 concentration effects of partner drugs of artemisinin and derivatives on recurrent episodes of uncomplicated Plasmodium falciparum malaria after repetitive treatment with the same drug during two years in Mali."},{"key":"10.1016\/j.ijid.2022.08.020_bib0047","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/bdd.1786","article-title":"Gender differences in pharmacokinetics of lumefantrine and its metabolite desbutyl-lumefantrine in rats","volume":"33","author":"Wahajuddin, Singh","year":"2012","journal-title":"Biopharmaceutics & drug disposition"},{"key":"10.1016\/j.ijid.2022.08.020_bib0048","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.pt.2008.01.006","article-title":"Simplified antimalarial therapeutic monitoring: using the day-7 drug level?","volume":"24","author":"White","year":"2008","journal-title":"Trends in parasitology"},{"key":"10.1016\/j.ijid.2022.08.020_bib0049","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2165\/00003088-199937020-00002","article-title":"Clinical pharmacokinetics and pharmacodynamics of artemether-lumefantrine","volume":"37","author":"White","year":"1999","journal-title":"Clinical pharmacokinetics"},{"key":"10.1016\/j.ijid.2022.08.020_bib0050","first-page":"1254","article-title":"Sex-based differences in drug activity","volume":"80","author":"Whitley","year":"2009","journal-title":"American family physician"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971222004908?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971222004908?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T08:09:32Z","timestamp":1761120572000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971222004908"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":49,"alternative-id":["S1201971222004908"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2022.08.020","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lumefantrine plasma concentrations in uncontrolled conditions among patients treated with artemether-lumefantrine for uncomplicated plasmodium falciparum malaria in Mwanza, Tanzania","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2022.08.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}]}}